Head & Neck Cancer

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally advanced head and neck cancer.

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck squamous cell carcinoma.

Missing weekly cisplatin cycles was associated with worse OS in patients with head and neck cancers, particularly for those with p16-negative tumors.

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.

From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, here is this week’s news.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.

Patients with a head and neck cancer subtype did not show differences in survival outcomes when treated with radiation versus transoral robotic surgery.

An oral gel to manage oral mucositis — or chemo mouth — may help alleviate the effects of the side effect related to chemotherapy and radiotherapy.

A Keytruda-based regimen given both before and after surgery for patients with head and neck squamous cell carcinoma may improve event-free survival.

In some patients with head and neck cancer, those who require dental care after cancer treatment may face financial burdens because of out-of-pocket costs.

In addition to increased treatment costs, patients with head and neck cancers also experienced therapy changes during the cisplatin shortage.

A trial showed no overall survival or progression-free survival benefit from the addition of UV1 to Keytruda in patients with HNSCC.

From Patti Yasutake’s death from cancer to Olympic water polo player’s husband’s rare cancer diagnosis, here’s what’s happening in the oncology space this week.

CURE® spoke to an expert from Emory University in Atlanta about tonsil cancer, its “gold standard” treatment and potential side effects.

Patients with head and neck squamous cell carcinoma can talk to their care team about a trial evaluating petosemtamab for recurrent or metastatic disease.

Updated data has been reported evaluating efti and Keytruda in PD-L1 negative recurrent or metastatic head and neck squamous cell carcinoma.

From the lead singer of Heart’s cancer diagnosis and postponing their tour to Dick Vitale’s upcoming cancer surgery, here’s what’s going on in the cancer space this week.

The immunotherapy Opvido and reirradiation resulted in a one-year progression-free survival rate of 61.7% among certain patients with head and neck cancer.

When compared with unvaccinated patients, HPV vaccines were associated with lower rates of HPV-related cancer for people younger than 40.

A breakthrough therapy designation was granted to petosemtamab by the FDA to treat patients with recurrent or metastatic head and neck cancers.

Patients with laryngeal cancer who stopped smoking before receiving treatment had better survival outcomes, compared with patients who actively smoke.

Cancer is an emotionless assassin that can attack us and the ones we love most.

Of all the bad whatifs about cancer that creep into my ear, what if I turned them into positive whatifs?

From Jason Kelce honoring the team trainer who has been diagnosed with cancer to deaths in the sports reporting and music world, here’s what’s happening in the oncology space this week.

Treatment paradigms may soon be shifting in head and neck cancer, as recent research indicates that lower doses of chemoradiotherapy may be appropriate for some patients.

Substance use disorders, such as alcohol use disorder, were found to be more prevalent among survivors of specific cancer types, according to research.

The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.